Orthocell Limited (OCC.AX)
AUD 1.58
(-1.25%)
AUD 1.58
(-1.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 5.31 Million AUD | 25.27% |
| 2023 | 4.24 Million AUD | 177.01% |
| 2022 | 1.53 Million AUD | 50.47% |
| 2021 | 1.01 Million AUD | 41.48% |
| 2020 | 719.52 Thousand AUD | -23.91% |
| 2019 | 945.65 Thousand AUD | 52.73% |
| 2018 | 619.17 Thousand AUD | 16.87% |
| 2017 | 529.81 Thousand AUD | -20.51% |
| 2016 | 666.49 Thousand AUD | -15.68% |
| 2015 | 790.43 Thousand AUD | 14.32% |
| 2014 | 691.4 Thousand AUD | 31.88% |
| 2013 | 524.28 Thousand AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 5.31 Million AUD | 25.27% |
| 2024 Q2 | 2.55 Million AUD | 0.0% |
| 2024 Q4 | 3.9 Million AUD | 0.0% |
| 2023 FY | 4.24 Million AUD | 177.01% |
| 2023 Q2 | 846.85 Thousand AUD | 0.0% |
| 2023 Q4 | 3.39 Million AUD | 0.0% |
| 2022 Q2 | 764.09 Thousand AUD | 0.0% |
| 2022 Q4 | 767.62 Thousand AUD | 0.0% |
| 2022 FY | 1.53 Million AUD | 50.47% |
| 2021 FY | 1.01 Million AUD | 41.48% |
| 2021 Q4 | 571.76 Thousand AUD | 0.0% |
| 2021 Q2 | 446.2 Thousand AUD | 0.0% |
| 2020 FY | 719.52 Thousand AUD | -23.91% |
| 2020 Q4 | 351.42 Thousand AUD | 0.0% |
| 2020 Q2 | 368.09 Thousand AUD | 0.0% |
| 2019 FY | 945.65 Thousand AUD | 52.73% |
| 2019 Q4 | 438.78 Thousand AUD | 0.0% |
| 2019 Q2 | 506.87 Thousand AUD | 0.0% |
| 2018 Q2 | 293.38 Thousand AUD | 0.0% |
| 2018 FY | 619.17 Thousand AUD | 16.87% |
| 2018 Q4 | 325.79 Thousand AUD | 0.0% |
| 2017 FY | 529.81 Thousand AUD | -20.51% |
| 2017 Q2 | 309.02 Thousand AUD | 0.0% |
| 2017 Q4 | 220.79 Thousand AUD | 0.0% |
| 2016 Q2 | 450.83 Thousand AUD | 0.0% |
| 2016 Q4 | 215.66 Thousand AUD | 0.0% |
| 2016 FY | 666.49 Thousand AUD | -15.68% |
| 2015 Q2 | 384.34 Thousand AUD | 0.0% |
| 2015 Q4 | 406.08 Thousand AUD | 0.0% |
| 2015 FY | 790.43 Thousand AUD | 14.32% |
| 2014 FY | 691.4 Thousand AUD | 31.88% |
| 2014 Q4 | 289.69 Thousand AUD | 0.0% |
| 2014 Q2 | 401.71 Thousand AUD | 0.0% |
| 2013 FY | 524.28 Thousand AUD | 0.0% |
| 2013 Q3 | - AUD | -100.0% |
| 2013 Q4 | 229.34 Thousand AUD | 0.0% |
| 2013 Q2 | 294.94 Thousand AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | -205.868% |
| Acrux Limited | 5.09 Million AUD | -4.407% |
| Amplia Therapeutics Limited | 4.45 Million AUD | -19.373% |
| Biome Australia Limited | 13 Million AUD | 59.14% |
| BTC Health Limited | 16.36 Thousand AUD | -32390.067% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 28.726% |
| CSL Limited | 22.41 Billion AUD | 99.976% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 53.806% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 93.972% |
| Noxopharm Limited | 2.4 Million AUD | -121.448% |
| PharmAust Limited | - AUD | -Infinity% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -495.799% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -43.18% |
| PYC Therapeutics Limited | 22.05 Million AUD | 75.904% |
| Race Oncology Limited | 4 Million AUD | -32.769% |
| Starpharma Holdings Limited | 8.28 Million AUD | 35.874% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 92.0% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -783.217% |
| Memphasys Limited | 60 Thousand AUD | -8758.958% |
| Nyrada Inc. | - AUD | -Infinity% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 98.93% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -28914.056% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -5497.96% |
| Patrys Limited | 1.39 Million AUD | -281.259% |
| Dimerix Limited | 583.47 Thousand AUD | -810.981% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 97.708% |
| Imugene Limited | - AUD | -Infinity% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -129.542% |
| Immutep Limited | 3.5 Million AUD | -51.62% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -31166.912% |
| Alterity Therapeutics Limited | 4.01 Million AUD | -32.247% |
| Nanollose Limited | 12.5 Thousand AUD | -42419.598% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -338.47% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -324.695% |
| Biotron Limited | - AUD | -Infinity% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1676.363% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -3391.444% |
| AnteoTech Limited | 460.39 Thousand AUD | -1054.52% |
| Hexima Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -7978.078% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -1022.45% |
| Actinogen Medical Limited | 9.93 Million AUD | 46.48% |
| Immuron Limited | 4.9 Million AUD | -8.414% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -104.6% |